Analysis of Psychiatric Adverse Events for Semaglutide, Liraglutide, and Tirzepatide Reported to the EudraVigilance Database

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medicines that mimic the effects of GLP1 to regulate blood sugar levels.

The FDA first approved liraglutide in 2010 for the 2 treatment of type 2 diabete 1 .

In Glucagon was also approved for the.

treat GLP-1RAs obesity, whereas tirzepatide was first approved by th GLP-1 in 2022.

The aim of this study was to identify and analyse the reported occurrence of psychiatric adverse events and clinical outcomes for three anti- GLP-1 tic and anti-obesity medications.

The European Medicine Agency (EMA) 2 s safety committee, PRA 2–5 is reviewing data on the risk of thoughts of suicide and self-harm associated with GLP GLP-1 ceptor agonists. EMA GLP-1 EV incretin hormones n> three Text__NxlGi">EudraVigilance three 15 14 FDA _NxlGi">13 2010 maryFeed_highLightText__Nxl 2 i">GLP-12014 span class="summaryFeed_highLightText__NxlGi">25 first highLightText__Nx FDA ">25 2022 an> 2 d_highLightText__NxlGi">Saxenda 10 tText__NxlGi">GLP- 2.4 span> weekly ass="summaryFeed_highLightText__NxlGi">PRAC EMA11 the European Medicine Agencysix seven hLightText__NxlGi">July 2023 24 GLP- ER As 24 12 lGi">GLP-1RAs GLP-1 class="summaryFeed_highLightText__NxlGi">23 23 Marso et al ss= 2016 maryFeed_highLightText__NxlGi">2 Depression 6.2% ghLightText__NxlGi">22 5.0% mmaryFeed_highLightText Thirteen >21 1< 5 span> 2009 GIT ummaryFeed_highLightText__NxlGi">EMA 13 Gi">the European Medicines Agency 13 006 Frias >Europe al. pa 2021 GIT class="summaryFeed_highLightText__NxlGi">20 FDA between 6–22% ="summaryFeed_highLightText__NxlGi">CB1 14 _highLightText__NxlGi">first 19 2 LightText__NxlGi" GIT Neuropsychiatric 15 t__NxlGi">17 GLP-1 summaryFeed_highLightText__NxlGi">T2DM dyspepsia 16